SOTACPharmaceuticals
Sotac Pharmaceuticals Ltd — Profit & Loss Statement
₹109.25
+0.00%
Sotac Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 29398.77 | 0.17 Cr | 0.00 | 0.00 |
| Tax Rate For Calcs | 0.10 | 0.30 | 0.00 | 0.30 |
| Normalized EBITDA | 8.59 Cr | 7.53 Cr | 1.13 Cr | 1.53 Cr |
| Total Unusual Items | 0.03 Cr | 0.58 Cr | 0.00 | 0.00 |
| Total Unusual Items Excluding Goodwill | 0.03 Cr | 0.58 Cr | 0.00 | 0.00 |
| Net Income From Continuing Operation Net Minority Interest | 4.28 Cr | 2.88 Cr | 0.00 | -2.37 Cr |
| Reconciled Depreciation | 3.10 Cr | 2.28 Cr | 1.13 Cr | 2.59 Cr |
| Reconciled Cost Of Revenue | 80.35 Cr | 58.37 Cr | 0.00 | 39.83 Cr |
| EBITDA | 8.62 Cr | 8.11 Cr | 1.13 Cr | 1.53 Cr |
| EBIT | 5.51 Cr | 5.83 Cr | 0.00 | -1.06 Cr |
| Net Interest Income | -1.69 Cr | -2.00 Cr | 0.00 | -0.95 Cr |
| Interest Expense | 1.55 Cr | 1.90 Cr | 0.00 | 1.00 Cr |
| Interest Income | 0.05 Cr | 0.05 Cr | 0.05 Cr | 0.07 Cr |
| Normalized Income | 4.25 Cr | 2.47 Cr | 0.00 | -2.37 Cr |
| Net Income From Continuing And Discontinued Operation | 4.28 Cr | 2.88 Cr | 0.00 | -2.37 Cr |
| Total Expenses | 98.32 Cr | 72.24 Cr | 0.00 | 49.95 Cr |
| Rent Expense Supplemental | 0.04 Cr | 0.04 Cr | 0.02 Cr | 0.00 |
| Diluted Average Shares | 1.10 Cr | 1.10 Cr | 1.10 Cr | 1.10 Cr |
| Basic Average Shares | 1.10 Cr | 1.10 Cr | 1.10 Cr | 1.10 Cr |
| Diluted EPS | 3.90 | 2.61 | 0.00 | -2.14 |
| Basic EPS | 3.90 | 2.61 | 0.00 | -2.14 |
| Diluted NI Availto Com Stockholders | 4.28 Cr | 2.88 Cr | 0.00 | -2.37 Cr |
| Net Income Common Stockholders | 4.28 Cr | 2.88 Cr | 0.00 | -2.37 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 4.28 Cr | 2.88 Cr | 0.00 | -2.37 Cr |
| Minority Interests | 0.70 Cr | 0.59 Cr | — | — |
| Net Income Including Noncontrolling Interests | 4.28 Cr | 2.88 Cr | 0.00 | -2.37 Cr |
| Net Income Continuous Operations | 4.28 Cr | 2.88 Cr | 0.00 | -2.37 Cr |
| Tax Provision | 0.38 Cr | 1.64 Cr | 0.00 | 0.31 Cr |
| Pretax Income | 3.96 Cr | 3.93 Cr | 0.00 | -2.06 Cr |
| Other Non Operating Income Expenses | 0.12 Cr | 0.10 Cr | 0.04 Cr | 21000.00 |
| Special Income Charges | -0.10 Cr | 0.58 Cr | 0.00 | 0.00 |
| Other Special Charges | 0.20 Cr | -0.58 Cr | 1.84 Cr | — |
| Write Off | -0.10 Cr | — | — | — |
| Net Non Operating Interest Income Expense | -1.69 Cr | -2.00 Cr | 0.00 | -0.95 Cr |
| Total Other Finance Cost | 0.19 Cr | 0.14 Cr | 0.07 Cr | 0.03 Cr |
| Interest Expense Non Operating | 1.55 Cr | 1.90 Cr | 0.00 | 1.00 Cr |
| Interest Income Non Operating | 0.05 Cr | 0.05 Cr | 0.05 Cr | 0.07 Cr |
| Operating Income | 5.51 Cr | 5.24 Cr | 0.00 | -1.11 Cr |
| Operating Expense | 17.98 Cr | 13.87 Cr | 0.00 | 10.12 Cr |
| Other Operating Expenses | 5.90 Cr | 3.92 Cr | 1.63 Cr | 2.81 Cr |
| Depreciation And Amortization In Income Statement | 3.10 Cr | 2.28 Cr | 0.00 | 2.59 Cr |
| Depreciation Income Statement | 3.10 Cr | 2.28 Cr | 0.00 | 2.59 Cr |
| Selling General And Administration | 0.68 Cr | 0.96 Cr | 0.25 Cr | 0.62 Cr |
| Selling And Marketing Expense | 0.13 Cr | 0.12 Cr | 0.01 Cr | 0.36 Cr |
| General And Administrative Expense | 0.56 Cr | 0.84 Cr | 0.23 Cr | 0.26 Cr |
| Rent And Landing Fees | 0.04 Cr | 0.04 Cr | 0.02 Cr | 0.00 |
| Gross Profit | 23.48 Cr | 19.11 Cr | 0.00 | 9.01 Cr |
| Cost Of Revenue | 80.35 Cr | 58.37 Cr | 0.00 | 39.83 Cr |
| Total Revenue | 103.83 Cr | 77.48 Cr | 0.00 | 48.84 Cr |
| Operating Revenue | 103.83 Cr | 77.48 Cr | 0.00 | 48.84 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sotac Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.